1. Home
  2. CUE vs ADAG Comparison

CUE vs ADAG Comparison

Compare CUE & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • ADAG
  • Stock Information
  • Founded
  • CUE 2014
  • ADAG 2011
  • Country
  • CUE United States
  • ADAG China
  • Employees
  • CUE N/A
  • ADAG N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • ADAG Biotechnology: Pharmaceutical Preparations
  • Sector
  • CUE Health Care
  • ADAG Health Care
  • Exchange
  • CUE Nasdaq
  • ADAG Nasdaq
  • Market Cap
  • CUE 91.9M
  • ADAG 81.9M
  • IPO Year
  • CUE 2018
  • ADAG 2021
  • Fundamental
  • Price
  • CUE $1.49
  • ADAG $1.76
  • Analyst Decision
  • CUE Strong Buy
  • ADAG Strong Buy
  • Analyst Count
  • CUE 5
  • ADAG 1
  • Target Price
  • CUE $5.00
  • ADAG $8.00
  • AVG Volume (30 Days)
  • CUE 254.0K
  • ADAG 153.3K
  • Earning Date
  • CUE 03-10-2025
  • ADAG 03-09-2025
  • Dividend Yield
  • CUE N/A
  • ADAG N/A
  • EPS Growth
  • CUE N/A
  • ADAG N/A
  • EPS
  • CUE N/A
  • ADAG N/A
  • Revenue
  • CUE $9,532,000.00
  • ADAG $815,746.00
  • Revenue This Year
  • CUE $73.11
  • ADAG N/A
  • Revenue Next Year
  • CUE $11.02
  • ADAG $2.70
  • P/E Ratio
  • CUE N/A
  • ADAG N/A
  • Revenue Growth
  • CUE 149.53
  • ADAG N/A
  • 52 Week Low
  • CUE $0.45
  • ADAG $1.64
  • 52 Week High
  • CUE $2.37
  • ADAG $3.65
  • Technical
  • Relative Strength Index (RSI)
  • CUE 58.61
  • ADAG 42.36
  • Support Level
  • CUE $1.22
  • ADAG $1.64
  • Resistance Level
  • CUE $1.50
  • ADAG $1.95
  • Average True Range (ATR)
  • CUE 0.12
  • ADAG 0.10
  • MACD
  • CUE 0.00
  • ADAG 0.00
  • Stochastic Oscillator
  • CUE 96.67
  • ADAG 37.50

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About ADAG Adagene Inc.

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Share on Social Networks: